About MS Views and News

Within this blog you will find thousands of valuable MS related articles and resources which will enable you to learn and feel empowered with key Multiple Sclerosis information.

Please Visit our Website: www.msvn.org and our Social media platforms: Facebook, Twitter, and Instagram. Each providing knowledge for those affected by MS. *

From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Be empowered with MS news. CLICK HERE -to Subscribe forThe MS BEACON eNewsletter

Plus, learn from the MS Views and News Learning Channel on YouTube: www.youtube.com/msviewsandnews:


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, December 20, 2008

Popular Hypothesis Concerning Emergence Of Multiple Sclerosis Contested

Science Daily

ScienceDaily (Dec. 20, 2008) — During an autoimmune disease, the endogenous defence system (the immune system) loses the ability to distinguish between "self" and "foreign." As a consequence, the immune system directs its defence against itself, with fatal consequences. In the case of multiple sclerosis, a chronic, inflammatory autoimmune disease, the immune system attacks the protective layer encapsulating the nerve fibres: This protective layer formed by myelin works like insulation for electrical cables. If the insulation is damaged, the nerves can no longer transmit messages effectively.

» Read More

Suggestions, Comments and/or Questions are always appreciated.. - Thank you

Cognition Pharmaceuticals Announces: Positive Memory Results For Phase II Trial Of C105 In Multiple Sclerosis

Medical News Today Article Date: 18 Dec 2008

- Cognition Pharmaceuticals LLC announced positive results from a Phase 2 clinical trial of C105 (l amphetamine sulfate) on 151 Multiple Sclerosis patients with documented cognitive dysfunction.In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the Brief Visuospatial Memory Test - Revised, Total Recall (p = 0.041) and Delayed Recall (p < 0.01), and the California Verbal Learning Test, Long Delay Free Recall (p = .012). Safety data were unremarkable with a limited side-effect profile.
» Read More

Suggestions, Comments and/or Questions are always appreciated.. - Thank you

Friday, December 19, 2008

Keeping your Brain Healthy

Rec'd with this months AARP e-Newsletter:

50 Ways to Keep Your Brain Healthy

Research shows that the things you do every day can actually
exercise your brain. Our brain teasers range from
snacking on walnuts to ballroom dancing.
Check them out!

Click here to continue »

Related Link:
Five Tools for Improving Your Memory


Multiple Sclerosis Patient who was using Tysabri developed PML (a Brain illness) has died


Biogen Says Tysabri Patient With Brain Illness Died

By Elizabeth Lopatto

Dec. 19 (Bloomberg) -- A multiple sclerosis patient who developed a severe brain infection after taking Biogen Idec Inc. and Elan Corp.’s Tysabri, the fourth case reported in five months, has died, according to Biogen.

Cambridge, Massachusetts-based Biogen was informed of the American woman’s death two days ago, company spokeswoman Naomi Aoki said in an interview.

The company reported on Oct. 29 that the patient had been diagnosed with the brain illness, progressive multifocal leukoencephalopathy (PML).

Comments and/or Questions are always appreciated..

From the Nat'l MS Society: MS Learn Online Presents

Today's new Feature Presentations focus on employment issues.
This Feature Presentation will discuss common barriers to employment as a result of MS and how to overcome those barriers, as well as how to access rehabilitation counseling.

MS in the Workplace
This Feature Presentation examines the issues of MS in the workplace from the perspective of the employer.

Suggestions, Comments and/or Questions are always appreciated.. - Thank you

Very Cool online Radio (Entertainment)

Received from Sheryl in Miami

Very Cool online Radio:
Type a song or your favorite artist and it will bring it up
and then keep playing songs from that era

Click on the middle tab and you will get a list
of all kinds of music.


Make Others Smile...
Do you have an item to share with others?


Who is your real friend? - (Humor)

My father's humor:

Who is your real friend?

This really works...!
If you don't believe it, just try this experiment:

Put your dog and your spouse in the trunk of the car for an hour.

When you open the trunk, who is really happy to see you?


Wednesday, December 17, 2008

Multiple sclerosis drug natalizumab may reduce immunity

News-Medical Net
Published: Tuesday, 16-Dec-2008

A drug used to treat multiple sclerosis might make some patients vulnerable to brain infection by reducing the number of immune cells there, researchers at UT Southwestern Medical Center have found.

The findings also suggest that the drug, natalizumab, might be safer and more effective when given with treatment "holidays" instead of continuously over long periods, the researchers said.

"Natalizumab is very effective in keeping pro-inflammatory cells out of the brain to reduce damage from MS," said Dr. Olaf St?>, assistant professor of neurology at UT Southwestern and senior author of the study, which appears in the December issue of Archives of Neurology.

But the potential downside is interference with immune surveillance against infection, he said. Thus, infections of the brain or spinal cord may go undetected until they become a serious problem.

Continue reading by clicking here ( taking you to the originating site)

Suggestions, Comments and/or Questions are always appreciated.. - Thank you

4th case of PML in 2008 for Multiple Sclerosis patient on Tysabri

Reported by Trent S.-in Miami -- thanks Trent

Biotechnology companies Biogen Idec Inc. and Elan Corp. on Monday reported the fourth case this year of a deadly brain infection in a patient taking their multiple-sclerosis drug Tysabri.

The companies said they notified relevant regulatory agencies about the patient, located in the European Union, on Dec. 11. That patient has received about 26 months of Tysabri for the autoimmune condition multiple sclerosis and is being treated by a physician.

The drug has been facing pressure on the market since August, when the companies reported two new cases of the brain infection called progressive multifocal leukoencephalopathy, or PML. A third case was reported in November. More than 35,500 patients are taking the drug worldwide.

The companies have argued the risks, which are on the drug's label, are outweighed by the benefit the drug provides to multiple sclerosis patients. Tysabri was pulled from the market in 2005 after being linked to PML but reintroduced under restricted sales conditions in mid-2006.

Source: CNNMoney.com © 2008 Cable News Network.(15/12/08)

Suggestions, Comments and/or Questions are always appreciated.. - Thank you

Tuesday, December 16, 2008

Think Tank Examines How to Turn More Lab Discoveries into New Therapies for Progressive MS

National MS Society
Dec 12, 2008

What are the barriers to finding therapies that can stop and reverse the nervous system injury caused by multiple sclerosis? A think tank held by Fast Forward, LLC, the National MS Society’s drug discovery venture, in collaboration with Harvard’s NeuroDiscovery Center, gathered representatives from venture capital firms, voluntary health and patient advocacy groups, pharmaceutical and biotechnology companies, and university-based research scientists to share information and ideas around this issue and ways to overcome them.

» Read More

Suggestions, Comments and/or Questions are always appreciated.. - Thank you

Oral FTY720 (Fingolimod) Reduced Relapse Rate More Effectively Than...

Nat'l MS Society News
Dec 12, 2008

Before reading the information found below, please take note that if you are not yet using a mainstream MS medication and would like to enroll in an FTY720 clinical trial, contact your doctor to learn of a study location nearest you. OR, if in South Florida, Click HERE to see where you can enroll and/or obtain further information on FTY720..

Oral FTY720 (Fingolimod) Reduced Relapse Rate More Effectively Than Avonex in Initial Results of One-Year Study in Relapsing-Remitting MS

The experimental oral drug FTY720 (fingolimod, Novartis) reduced relapses significantly more than Avonex® (interferon beta-1a, Biogen Idec) in a one-year study involving 1,292 people with relapsing-remitting MS. Serious adverse events in the FTY720 group included two deaths from herpes infections and seven cases of localized skin cancer. These initial results are reported in a press release from Novartis, which notes that analysis of these data is ongoing and that two other large-scale, phase 3 trials of the drug are ongoing. The company expects to submit an application to the FDA for approval by the end of 2009.

Suggestions, Comments and/or Questions are always appreciated.. - Thank you

Sunday, December 14, 2008

Estriol to be studied as MS treatment in UCLA trial

Estriol to be studied as MS treatment in UCLA trial
Los Angeles Times - CA,USA
To try to develop kinder and more effective treatments for MS, Dr. Rhonda Voskuhl, director of the UCLA multiple sclerosis program, is reexamining the ...

Click above to read

The Secret Lives Of Bloggers (And ALL Human Beings)...

The Secret Lives Of Bloggers (And ALL Human Beings)...
My goal has always been (and will continue to be) to provide a public forum for those dealing with Multiple Sclerosis in which there is education, common bonding, and a sense of community provided in what I have tried to mask behind ...

Click the above link to read BRAINCHEESE